A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.
SOURCE: Empr.com
Web Development | Code Refactoring | Graphic Design | Photography Service
A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.
SOURCE: Empr.com